Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Sarcoma 4Glioma 4Thyroid Neoplasms 3Colorectal Neoplasms 3Central Nervous System Neoplasms 3Wilms Tumor 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms 2Multiple Myeloma 2Melanoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Xanthogranuloma, Juvenile 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumors Harboring NTRK Fusion 1Sarcoma, Ewing 1

Interventions

selitrectinib 2larotrectinib 1Suspensions 1Solutions 1Receptor Protein-Tyrosine Kinases 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Tumors Harboring NTRK Fusion × larotrectinib × Clear all
NCT02122913 2026-02-05

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Bayer

Phase 1 Completed
75 enrolled 2 FDA
Other solid neoplasm

Solid Tumors Harboring NTRK Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡